Anatara Lifesciences CEO Steve Lydeamore sat down with Anna Napoli at Finance News Network. The Finance News Network is Australia’s largest provider of online business and finance news.

Steve sat down with Anna to talk about our upcoming clinical studies and lead Gastrointestinal Reprogramming dietary supplement product candidate for Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Steve discusses the completion of our pre-clinical in vitro proof of concept studies, which demonstrated our products’ ability to address three shared characteristics of these conditions – inflammation, impaired intestinal barrier function and mucosal damage. The timeframe for partnering our dietary supplement product candidate is 18 to 24 months.